Novavax Inc (NVAX) — closed signal from May 3, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 1, 2026.
Predicted vs. what happened
NVAX price · publication thesis → realized outcomesplit-adjusted
$7.60 – $8.30Entry zone — fair-value band
$8.04Published — price the day we called it
$9.49Target — the price the thesis aimed for
$11.61Peak — highest point inside the window, not a realized return
$7.32Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 3 days.
Peak price
$11.61
peak on May 27, 2026 — not a realized returnPeak gain
+44.3%
peak, from the publication priceWindow close
$7.32
end-of-window price, context onlyDays to target
3
Window
May 3, 2026 – August 1, 2026
The thesis — published May 3, 2026
Predicted growth
+18%
over the measurement windowTarget price
$9.49
the price the thesis aimed forEntry zone
$7.60 – $8.30
the fair-value band we waited forPrice at publication
$8.04
published May 3, 2026Confidence
65%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novavax is a higher-risk vaccine company that could move quickly because it is shifting to licensing, has deals with Sanofi and Pfizer, and has respiratory vaccine updates coming soon. Near-term earnings can swing sentiment. The balance sheet is helpful, but earnings swings and negative price momentum keep conviction limited despite recent gains.
Primary drivers
- Licensing focus lets the company scale with fewer assets
- Deals with Sanofi and Pfizer show the tech works
- Upcoming earnings and vaccine news could move the stock fast
- High biotech event risk keeps conviction cautious
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.